NOVN.SW Earnings — Novartis AG

SIX

Updated Oct 27, 2026

Price —

Market Cap $252.8B

P/E 23.7

52W Range — – —

When is NOVN.SW's next earnings date?

Novartis AG (NOVN.SW) has not announced its next earnings date yet. Its most recent earnings report was on Tuesday, October 27, 2026.

How did NOVN.SW do in its last earnings report?

In its most recent report on Oct 27, 2026, Novartis AG posted EPS of $2.04 versus the $1.88 estimate, a beat of 8.5%. Revenue was $12.02B against a $12.16B estimate.

How much does NOVN.SW stock move after earnings?

NOVN.SW beat EPS estimates in 1 of its last 1 reported quarter.

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

🤖 AI Earnings Analysis

Novartis delivered a mixed quarter: EPS of $2.04 beat estimates by $0.17, but revenue of $12.0B missed by $0.2B. Reported growth is exceptionally high, though no catalyst or guidance update was provided.

AI-generated summary — powered by BigEarnings.